Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Shashank Sinha

Advanced Heart Failure · Inova Fairfax Hospital

View

Dr. Javed Butler

Advanced Heart Failure · Baylor Health Care System

View

Dr. Andrew Sauer

Advanced Heart Failure · Saint Luke's

View

Dr. Anu Lala

Advanced Heart Failure · Mount Sinai

View

Dr. Robert Mentz

Advanced Heart Failure · Duke University

View

Dr. Sunny Varshney

Advanced Heart Failure · Stanford

View

Dr. Stephanie Hsiao

Advanced Heart Failure · Stanford

View

Dr. Michelle Kittleson

Advanced Heart Failure · Cedars-Sinai

View

Dr. Adrian Hernandez

Advanced Heart Failure · Duke

View

Dr. Dorairaj Prabhakaran

General Cardiology

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    In-Hospital or Out-of-Hospital Initiation of Sacubitril/Valsartan Versus Valsartan in Patients With Mildly Reduced or Preserved Ejection Fraction After A Worsening Heart Failure Event: The PARAGLIDE-HF Trial.

    Feb 19, 2025DOI: 10.1161/jaha.124.037899Journal ArticleAHA

    Written by: Nina NouhraveshDerek CyrAdrian F HernandezDavid A MorrowEric J VelazquezJonathan WardSamiha SarwatKavita SharmaKristin WilliamsonRandall C StarlingSerge LepageShelley ZierothScott D SolomonRobert J Mentz

    Find these authors on Roon

    KS
    Dr. Kavita Sharma
    Advanced Heart Failure · Johns Hopkins

    METHODS

    The study design, rationale, and primary results of the PARAGLIDE‐HF trial have been published elsewhere.3, 6 Briefly, PARAGLIDE‐HF was a multicenter, double‐blind randomized controlled trial of Sac/Val versus Val with the primary efficacy end point of time‐averaged proportional change in NT‐proBNP in patients with left ventricular EF >40% with a recent WHF event. Patients were randomly assigned 1:1 to Sac/Val titrated to a target dose of 97/103 mg twice daily or Val titrated to 160 mg twice daily. Screening occurred during hospitalization for WHF or within 30 days of the WHF event. WHF was defined as hospitalization, emergency department visit, or out‐of‐hospital urgent HF visit, all requiring IV diuretics. Initial follow‐up was performed at week 1, week 4, and week 8 with additional subsequent visits. In addition to an HF diagnosis, EF >40%, and a WHF event within 30 days, patients were required to be ≥18 years of age, with an elevated NT‐proBNP/B‐type natriuretic peptide, and hemodynamically stabilized, defined as systolic blood pressure >100 mm Hg with no increase in IV diuretics, all within 6 hours of randomization and no IV inotropes within 24 hours of randomization.In this prespecified subgroup analysis, we used the full analysis set from the PARAGLIDE‐HF trial. This data set comprised all patients who were assigned study treatment through randomization and had received at least 1 dose of the treatment. Patients were categorized according to the location of initiation: in‐hospital and out‐of‐hospital initiation. Randomization in‐hospital was made after stabilization and no earlier than 36 hours from a potential dose of an angiotensin‐converting enzyme inhibitor. Randomization out‐of‐hospital was made within 30 days following a WHF event.The ethics committee at each trial center approved the primary trial, and all patients provided written informed consent. All supporting data are available within the article and its online supplementary files.The primary end point for efficacy was time‐averaged proportional change in NT‐proBNP from baseline to weeks 4 and 8, as detailed in the primary article,11 categorizing patients by location of initiation.Secondary end points included a win ratio analysis of a composite hierarchical outcome of time to cardiovascular death, number and timing of urgent HF hospitalizations during follow‐up, number and timing of urgent HF visits during follow‐up, and time‐averaged proportional change in NT‐proBNP from baseline to weeks 4 and 8. Additional secondary end points were the cumulative number of recurrent cardiovascular composite events including the number of HF hospitalizations, urgent HF visits, and cardiovascular deaths. Furthermore, a secondary composite end point of worsening renal function was investigated, defined as renal death, reaching end‐stage renal disease, or ≥50% decline in estimated glomerular filtration rate. Investigation of dosing levels and discontinuations of Sac/Val and Val and the incidence of adverse events of special interest, including symptomatic hypotension, hyperkalemia (potassium >5.5 mEq/L), worsening renal function defined as increase in serum creatinine of ≥0.5 mg/dL, and worsening estimated glomerular filtration rate by at least 25%, were likewise performed.
    Baseline characteristics of study participants are summarized according to location of initiation. Categorical variables are described with counts (percentages), and continuous variables are represented as median (25th–75th percentiles), unless stated otherwise.
    Participants were included in the analysis based on their assigned treatment group following randomization adhering to the intent‐to‐treat principle. The primary outcome, the time‐averaged proportional change of NT‐proBNP from baseline, was examined using an analysis of covariance model that incorporated data from weeks 4 and 8. This method was used to compare the efficacy of the 2 treatments, Sac/Val versus Val, administered in 2 distinct settings (in‐hospital and out‐of‐hospital); thus, outcomes between patients randomized in‐hospital versus out‐of‐hospital were not assessed in this analysis. The model included treatment group, location of initiation, sex, and baseline EF (less than or equal to median, greater than median) as fixed‐effect factors. Additionally, age and the logarithmic baseline NT‐proBNP were incorporated as covariates along with the interaction of treatment by location of initiation. The estimated treatment effect in terms of ratios of geometric means, based on the least‐squares means from the model, and the corresponding 2‐sided 95% CIs were presented by initiation of location. To evaluate the potential impact of missing NT‐proBNP data on the time‐averaged proportional change from baseline to weeks 4 and 8, baseline characteristics were reported for those with missing and nonmissing NT‐proBNP data.
    The secondary end point, a composite hierarchical outcome was estimated by an unmatched pair win ratio analysis, comparing each patient in the Sac/Val group to each patient in the Val group (162×162 and 71×71 total pairs in the in‐hospital and out‐of‐hospital groups, respectively) at each level of the hierarchy to determine a winner, as previously reported in depth by Mentz et al.8 Briefly, for example, for the first component of the hierarchy, cardiovascular death, the winner was the patient who experienced the event at the latest time point; if neither patient died, then the patient with fewer WHF events was the winner. For the last component of the hierarchy, NT‐proBNP, the patient with the larger decrease or smaller increase was considered the winner. The pairwise comparison was considered a tie if the proportional changes from 2 patients were between 0.75 and 1/0.75. The estimated win ratio was computed as the total number of wins in the Sac/Val group divided by the total number of wins in the Val group. A predefined win ratio >1.0 was established as favoring Sac/Val. Two‐sided 95% CIs and corresponding P values were calculated using a generalized analytic solution.12
    The cumulative number of composite cardiovascular events was estimated using the semiparametric proportional rates model.13 The rate ratio was estimated with treatment arm and in‐hospital/out‐of‐hospital randomization as fixed factors and the treatment‐by‐location of initiation interaction, through maximization of a partial likelihood score function. The 95% CIs were based on the robust estimate of the standard errors.
    Assessment of the composite end point of worsening renal function was conducted using a negative binomial regression model, including treatment group and location of initiation as fixed‐effect factors, along with the interaction term for location of initiation.
    Study drug dosage levels were summarized and stratified by location of initiation with differences estimated using the χ2 test or Fisher exact test, as appropriate. Drug dosages were categorized in 3 levels: (1) dose level 40 mg Val or 24/26 mg Sac/Val twice daily, (2) dose level 80 mg Val or 49/51 mg Sac/Val twice daily, or (3) dose level 160 mg Val or 97/103 mg Sac/Val twice daily.
    Finally, the incidence of adverse events of special interest were analyzed using logistic regression models with treatment group and location of initiation as fixed factors, as well as the interaction term for location of initiation.
    The above‐mentioned end points were also reported for the prespecified subgroup of patients with EF ≤60% stratified by location of initiation based on current label indications and guideline recommendations for Sac/Val.14
    All statistical tests were conducted against a 2‐sided alternative hypothesis using a significance level of 0.05. All analyses were performed with SAS software version 9.4 (SAS Institute, Cary, NC).

    RESULTS

    Of the 466 patients included in PARAGLIDE‐HF, 324 (69.5%) were initiated in‐hospital, whereas 142 (30.5%) were initiated out‐of‐hospital. For patients initiated out‐of‐hospital, 97% in the Sac/Val group and 99% in the Val group were included due to a WHF hospitalization within 30 days. The median number of days from the start of the enrolling event (ie, onset of WHF event) to randomization was 3 (Q1–Q3: 3–13) for patients randomized in‐hospital and 19 (Q1–Q3: 13–28) for patients randomized out‐of‐hospital (Table S1), and the duration of the qualifying hospitalization was 3.8 days for Sac/Val and 3.5 days for Val (Table S2). Baseline characteristics are presented in Table 1 by location of initiation and in Table S3 by location of initiation and treatment group. Approximately 50% of patients initiated in‐hospital were women, and approximately 24% were Black, compared with 56% women and 18% Black individuals in the out‐of‐hospital group. Lower EF and higher New York Heart Association class were observed for patients initiated in‐hospital. Baseline characteristics were similar among the subgroup of EF ≤60% (Table S4).
    Baseline Characteristics of Study Participants According to Location of Initiation
    ACEi indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BNP, B‐type natriuretic peptide; eGFR, estimated glomerular filtration rate; HF, heart failure; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NT‐proBNP, N‐terminal pro‐brain‐type natriuretic peptide; NYHA, New York Heart Association; and SGLT2i, sodium‐glucose cotransporter‐2 inhibitor.
    Available data for ischemic cause was found for 213 in the in‐hospital group and for 97 in the out‐of‐hospital group. For prior HF hospitalization, data were available for 215 in the in‐hospital group and 98 in the out‐of‐hospital group.
    A total of 75 (23.1%) patients randomized in‐hospital and 14 (9.9%) patients randomized out‐of‐hospital did not contribute to the primary end point of NT‐proBNP due to missing baseline measurements or missing measurements at both weeks 4 and 8. As seen in Table S5, baseline characteristics between those with missing and nonmissing NT‐proBNP were similar overall, with the exception of location of initiation. Patients with missing NT‐proBNP data were more frequently randomized in‐hospital than those with nonmissing NT‐proBNP data (84.3% versus 66.0%).
    As shown in Table 2, no statistically significant difference was observed in the treatment benefit of Sac/Val versus Val on NT‐proBNP by the location of initiation (P interaction=0.99). The overall time‐averaged reduction in NT‐proBNP was greater with Sac/Val compared with Val, irrespective of location of initiation, although statistically not significant (ratio of change at week 4 and 8 for in‐hospital, 0.86 [95% CI, 0.70–1.05]; out‐of‐hospital, 0.87 [95% CI, 0.70–1.09]) (Figure 1). The NT‐proBNP geometric mean values by study visit shown in Table S6 likewise show a greater reduction in NT‐proBNP concentration with Sac/Val compared with Val by week 4, irrespective of location of initiation. The proportional change in NT‐proBNP from baseline to week 4 and 8 is shown in Table S7. This analysis significantly favored Sac/Val, irrespective of location of initiation at week 4; this reduction was not statistically significant at week 8. No significant interaction was present by location of initiation.
    Primary End Point and Secondary End Points of Recurrent Composite Cardiovascular Events and Worsening Renal Function
    HF indicates heart failure; NT‐proBNP, N‐terminal pro‐brain‐type natriuretic peptide; Sac/Val, sacubitril/valsartan; and Val, valsartan.
    Geometric mean is exponentially back transformed from least‐squares means based on the ANCOVA model. The same transformation is applied to the 95% CIs.
    Recurrent composite cardiovascular events consisted of HF hospitalizations, urgent HF visits, and cardiovascular death.
    Worsening renal function was a composite consisting of renal death, reaching end‐stage renal disease (sustained estimated glomerular filtration rate <15 mL/min per 1.73 m2, chronic dialysis, or renal transplant) and ≥50% decline in estimated glomerular filtration rate relative to baseline.
    The time‐averaged reduction in NT‐proBNP concentration is shown according to location of initiation at baseline. Data are shown from baseline through weeks 4 and 8 with corresponding 95% CIs as indicated by the error bars. No significant interaction by location of initiation was observed (P interaction=0.99). The time‐averaged reduction in NT‐proBNP numerically favored sacubitril/valsartan compared with valsartan in both in‐hospital (0.86 [95% CI, 0.70–1.05]; P=0.14) and out‐of‐hospital (0.87 [95% CI, 0.70–1.09; P=0.22]). NT‐proBNP indicates N‐terminal pro‐B‐type natriuretic peptide.
    In the subgroup of patients with baseline EF ≤60%, the decrease in NT‐proBNP was greater with Sac/Val than Val, irrespective of the location of initiation. No statistically significant interaction was observed for the primary end point by location of initiation among patients with EF ≤60% (P interaction=0.82). The reduction seen with Sac/Val was even greater in this subgroup of patients with EF ≤60% than the overall population, both for patients randomized in‐hospital and those randomized out‐of‐hospital (Table S8).
    Differences in baseline characteristics for those with baseline EF ≤60% categorized by missing and nonmissing NT‐proBNP data were similar to those of the overall population (Table S9).
    The win ratio analyses numerically favored Sac/Val compared with Val. The win ratio of patients initiated out‐of‐hospital was 1.43 (95% CI, 0.91–2.26; P=0.12), whereas patients initiated in‐hospital had a win ratio of 1.09 (95% CI, 0.82–1.45; P=0.57) (Figure 2).
    The composite hierarchical outcome of CV death, HF hospitalizations, urgent HF visits, and change in NT‐proBNP was estimated by the unmatched win ratio by comparing every patient in the sacubitril/valsartan group to every patient in the valsartan group to determine a winner. The estimated win ratio (the total number of wins in the sacubitril/valsartan arm divided by the total number of wins in the valsartan arm) was calculated with corresponding 95% CIs. CV indicates cardiovascular; HF, heart failure; and NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide.
    As shown in Table 2, for the cumulative number of composite cardiovascular events, no statistically significant interaction by initiation of location was observed (P interaction=0.36). For patients initiated in‐hospital, there were 62 recurrent composite cardiovascular events in the Sacl/Val group and 65 cardiovascular events in the Val group, resulting in a rate ratio (RR) of 0.97 (95% CI, 0.60–1.56). For patients initiated out‐of‐hospital, there were 32 recurrent composite cardiovascular events in the Sac/Val group and 52 cardiovascular events in the Val group, resulting in an RR of 0.66 (95% CI, 0.34–1.29). Results were consistent in the subgroup of patients with baseline EF ≤60% (Table S8).
    As shown in Table 2, for the composite end point of worsening renal function, no statistically significant interaction by location of initiation was found (P interaction=0.14). For patients initiated in‐hospital, there were 22 worsening renal function events in the Sac/Val group and 26 events in the Val group, resulting in similar rates (RR, 1.03 [95% CI, 0.34–3.17]). Among patients initiated out‐of‐hospital, the RR numerically favored Sac/Val (RR, 0.25 [95% CI, 0.05–1.13]). Likewise, similar findings were evident for the subgroup of patients with baseline EF ≤60% (Table S8).
    As shown in Table S10, the distribution of study drug dosage levels (dosage levels 1, 2, and 3) was similar between treatment groups throughout all study visits irrespective of location of initiation. Drug dosage levels achieved were likewise similar between Sac/Val and Val in the subgroup with baseline EF ≤60% (Table S11).
    As presented in Table 3, for the adverse events of special interest, all interactions by location of initiation demonstrated an interaction P value >0.1. Sac/Val had more symptomatic hypotension compared with Val, irrespective of location of initiation, with an odds ratio (OR) of 1.74 (95% CI, 0.99–3.04) among the in‐hospital group and an OR of 1.72 (95% CI, 0.74–3.99) for patients initiated out‐of‐hospital. Furthermore, fewer events of worsening renal function occurred with Sac/Val compared with Val, irrespective of location of initiation. For the subgroups of patients with baseline EF ≤60%, similar findings were found for worsening renal function (in‐hospital OR, 0.56 [95% CI, 0.32–1.00] versus out‐of‐hospital OR, 0.59 [95% CI, 0.24–1.47]), whereas hypotension was more prevalent when initiated in‐hospital (OR, 1.47 [95% CI, 0.78–2.78]) than out‐of‐hospital (OR, 1.10 [95% CI, 0.40–3.03]) (Table S8).
    Adverse Events of Special Interest
    OR indicates odd ratio; Sac/Val, sacubitril/valsartan; and Val, valsartan.

    DISCUSSION

    In this predefined subgroup analysis of the PARAGLIDE‐HF trial, 324 (69.5%) patients were initiated in‐hospital, whereas 142 (30.5%) were initiated out‐of‐hospital. Compared with Val, the initiation of Sac/Val was well tolerated regardless of the location of initiation. Sac/Val showed a consistently greater reduction of NT‐proBNP compared with Val, irrespective of the timing and location of initiation relative to the qualifying WHF event. Likewise, the win ratio analyses numerically favored treatment with Sac/Val compared with Val. Moreover, tolerability and target dose reached was consistent with Sac/Val regardless of location of initiation.
    Prior evidence has shown 30‐day readmission and mortality rates following HF hospitalization of approximately 25% and 10%, respectively.1, 2 Unfortunately, limited evidence‐based strategies are available to reduce postdischarge outcomes in patients hospitalized for HF. However, a strong association between in‐hospital initiation of guideline‐recommended therapy and reduced the risk of readmission and mortality has been shown.15, 16 As such, a post hoc analyses of PARAGON‐HF revealed that initiating treatment with Sac/Val early postdischarge was linked to a greater reduction in the risk of HF hospitalization and cardiovascular death in patients with HF with an EF ≥45%.9 The lack of significant interactions by location of initiation on treatment outcomes in the current data set highlights the potential of initiating Sac/Val in‐hospital for those with EF >40%, while being mindful of the limited power for interaction testing resulting from the modest sample size in the current data set.
    As seen in the win ratio analysis, Sac/Val numerically reduced clinical events with no significant interaction by location of initiation. Thus, in line with the pooled analysis of PARAGLIDE‐HF and PARAGON‐HF, Sac/Val numerically reduced cardiovascular events compared with Val.17
    Safety considerations with Sac/Val, such as potential hypotension or worsening renal function, have been a concern of HF clinicians, limiting in‐hospital initiation. However, the safety end points of this study showed that in‐hospital initiation was not associated with an increase in adverse events. These findings extend the knowledge from the open‐label extension of PIONEER‐HF (Comparison of Sacubitril–Valsartan Versus Enalapril on Effect on NT‐proBNP in Patients Stabilized From an Acute Heart Failure Episode), which reported similar rates of worsening renal function, hyperkalemia, symptomatic hypotension, and angioedema for patients with HF with reduced EF switching from enalapril to Sac/Val compared with patients who did not cross over during the open‐label extension period. Thus, the data presented in the current study extend the safety of early initiation of Sac/Val to the entire spectrum of HF.18
    The clinical implications of initiating Sac/Val in‐hospital extend beyond logistical benefits. The possible advantages of in‐hospital initiation include enhanced adherence, monitoring, and clinical outcomes and offer a potential for optimizing HF management in patients with HF with EF >40%. In‐hospital initiation of pharmacotherapy presents a unique opportunity for thorough patient counseling and hemodynamic and laboratory monitoring. These advantages of in‐hospital initiation, in addition to the comparable effectiveness, safety, and tolerability of Sac/Val, irrespective of location of initiation, is particularly relevant in the current landscape in which early initiation of guideline‐directed medical therapy has been challenging.19, 20, 21
    The limitations of this predefined substudy of PARAGLIDE‐HF include primarily its modest sample size and limited statistical power. However, the current study addresses an important clinical question that had previously been unanswered. Although the sample size is modest, the results of this study provide insight into the potential differences according to location of initiation, which provide helpful empiric data for practicing clinicians. Furthermore, ≈19% of patients did not contribute to the primary end point due to missing NT‐proBNP data, which poses constraints to the interpretation of data, although baseline characteristics were relatively similar in those with missing NT‐proBNP data compared with those with available NT‐proBNP data. The lack of stratification by location of initiation should also be considered. Furthermore, for patients included in the out‐of‐hospital group, the qualifying event was hospitalization, and thus the representation of patients with an emergency department visit or an urgent HF visit was limited in this data set. Last, 1 patient randomized in‐hospital did not initiate therapy until 2 days postdischarge from the WHF event.

    CONCLUSIONS

    Sac/Val provided consistent benefits and was well tolerated compared with Val whether initiated in‐hospital or out‐of‐hospital after a recent WHF event in patients with EF >40%. Thus, in‐hospital initiation of Sac/Val is an opportunity for improvement of postdischarge outcomes.

    Acknowledgments

    The PARAGLIDE‐HF leadership appreciates the CardioNerds' collaboration in enhancing recruitment, ensuring equitable enrollment, and supporting trainee development.

    Sources of Funding

    PARAGLIDE‐HF was funded by Novartis Pharmaceuticals.

    Disclosures

    Dr Nouhravesh reports speaker fees from AstraZeneca and Bayer. Drs Ward, Williamson, and Sarwat are employees of Novartis. Dr Hernandez has received research grants from American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Merck, Novartis, Somologic, and Verily; and has served as a consultant for Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Merck, Novartis, and Novo Nordisk. Dr Morrow is a member of the TIMI Study Group, which has received institutional research grant support through Brigham and Women's Hospital from Abbott, Abiomed, Amgen, Anthos Therapeutics, ARCA Biopharma, AstraZeneca, Bayer HealthCare Pharmaceuticals, Daiichi‐Sankyo, Eisai, Intarcia, Ionis Pharmaceuticals, Janssen Research, Development, Merck, Novartis, Pfizer, Quark Pharmaceuticals, Regeneron Pharmaceuticals, Roche, Siemens Healthcare Diagnostics, Softcell Medical Limited, and Zora Biosciences; and has received consulting fees from Abbott Laboratories, ARCA Biopharma, Inflammatix, Merck, Novartis, and Roche Diagnostics. Dr Starling serves on the steering committee for the PARAGLIDE trial sponsored by Novartis. Dr Velazquez has received grants from Novartis, Amgen, Phillips, and the National Heart, Lung, and Blood Institute/National Institutes of Health. Dr Zieroth has received research grant support, served on advisory boards for, or has had speaker engagements with Abbott, Akcea, AstraZeneca, Amgen, Alnylam, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Janssen, Merck, Novartis, Novo Nordisk, Otsuka, Pfizer, Roche, Servier, and Vifor Pharma; and serves on a clinical trial committee or as a national lead for studies sponsored by AstraZeneca, Bayer, Boehringer Ingelheim, Merck, Novartis, and Pfizer. Dr Solomon has received research grants from Alnylam, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Cytokinetics, Eidos, GlaxoSmithKline, Ionis, Lilly, MyoKardia, National Institutes of Health/National Heart, Lung, and Blood Institute, Novartis, Novo Nordisk, Respicardia, Sanofi Pasteur, Theracos, Actelion, Amgen, Bellerophon, Celladon, Gilead, Mesoblast, Neurotronik, and Lure 11; and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi‐Sankyo, GlaxoSmithKline, Lilly, Merck, MyoKardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions; Tenaya, Sanofi‐Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, Sarepta, Lexicon, Anacardio, Akros, and Valo. Dr Mentz has received research support or honoraria from Novartis, Abbott, American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Fast BioMedical, Gilead, Innolife, Eli Lilly, Medtronic, Medable, Merck, Novo Nordisk, Pharmacosmos, Relypsa, Respicardia, Roche, Sanofi, Vifo; Windtree Therapeutics, and Zoll.

    Supporting information

    Tables S1–S11
    KSDr. Kavita Sharma

    Dr. Kavita Sharma

    Cardiology · Advanced Heart Failure & Transplantation
    Johns Hopkins Medicine
    kavita